Current blood cancer drug prices not justified, MD Anderson study finds
The costs associated with cancer drug prices have risen dramatically
over the past fifteen years, which is of concern to many top
oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center
concluded the majority of existing treatments for hematologic, or
blood, cancers are currently priced too high to be considered
cost-effective in the United States. Their findings are published in the
current issue of the journal Cancer.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news